Legislation & Regulation

Access the AMCP Legislative Days 2024 Education Slides, to learn the terminology most associated with a Member of Congress and understand key advocacy vocabulary to help explain AMCP’s positions on the the Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) and the Medicaid VBPs for Patients (MVP) Act  (H.R. 2666).

On Feb. 29, 2024, the Centers for Medicare and Medicaid Services (CMS) issued The Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents. AMCP submitted comments in response to this Model Documents on April 29, 2024.

On Feb. 15, 2024, the Centers for Medicare and Medicaid Services (CMS) issued the Medicare Prescription Payment Plan: Draft Part Two Guidance and a Fact Sheet to provide guidance on education and outreach requirements for the Medicare Prescription Payment Plan (M3P), which was established by the Inflation Reduction Act (IRA). AMCP submitted comments in response to this Guidance on March 15, 2024.

In a March 5, 2024 press release, the Department of Health & Human Services (HHS) expressed intent to issue guidance to encourage Medicare Advantage (MA) and Part D plans to relax or remove prior authorization requirements and other utilization management strategies. On March 6, 2024, CMS issued a memo encouraging MA and Part D plans to relax or remove prior authorization requirements in response to the Change Healthcare cyberatack. AMCP sent a letter in response to this guidance on March 8, 2024.

On January 31, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the Draft Guidance titled “Draft Part D Redesign Program Instructions (Program Instructions)”, concurrently with the Advance Notice. The Draft Part D Redesign Program Instructions provide draft guidance regarding the implementation of certain Inflation Reduction Act (IRA) provisions relating to the Part D drug benefit. CMS is soliciting comments on all aspects of the Guidance, and notes that policies established in the final Guidance are for 2025. AMCP submitted comments in response to this rule on March 1, 2024.